Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more
Modus Therapeutics Holding AB (MODTX) - Total Assets
Latest total assets as of December 2025: Skr12.69 Million SEK
Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) holds total assets worth Skr12.69 Million SEK as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Modus Therapeutics Holding AB - Total Assets Trend (2018–2025)
This chart illustrates how Modus Therapeutics Holding AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Modus Therapeutics Holding AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Modus Therapeutics Holding AB's total assets of Skr12.69 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 89.7% |
| Accounts Receivable | Skr1.31 Million | 10.4% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Modus Therapeutics Holding AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Modus Therapeutics Holding AB's current assets represent 100.0% of total assets in 2025, an increase from 99.9% in 2018.
- Cash Position: Cash and equivalents constituted 89.7% of total assets in 2025, down from 97.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 10.4% of total assets.
Modus Therapeutics Holding AB Competitors by Total Assets
Key competitors of Modus Therapeutics Holding AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Modus Therapeutics Holding AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Modus Therapeutics Holding AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Modus Therapeutics Holding AB is currently not profitable relative to its asset base.
Modus Therapeutics Holding AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.51 | 1.76 | 7.04 |
| Quick Ratio | 3.51 | 1.76 | 7.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr9.07 Million | Skr 2.08 Million | Skr 5.57 Million |
Modus Therapeutics Holding AB - Advanced Valuation Insights
This section examines the relationship between Modus Therapeutics Holding AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.88 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 159.7% |
| Total Assets | Skr12.69 Million |
| Market Capitalization | $859.70K USD |
Valuation Analysis
Below Book Valuation: The market values Modus Therapeutics Holding AB's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Modus Therapeutics Holding AB's assets grew by 159.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Modus Therapeutics Holding AB (2018–2025)
The table below shows the annual total assets of Modus Therapeutics Holding AB from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr12.69 Million | +159.75% |
| 2024-12-31 | Skr4.88 Million | -75.63% |
| 2023-12-31 | Skr20.04 Million | +77.81% |
| 2022-12-31 | Skr11.27 Million | -46.81% |
| 2021-12-31 | Skr21.19 Million | +182.89% |
| 2020-12-31 | Skr7.49 Million | +265.24% |
| 2019-12-31 | Skr2.05 Million | -95.63% |
| 2018-12-31 | Skr46.95 Million | -- |